|
1.
|
Jiang H and Ge J: Epidemiology and
clinical management of cardiomyopathies and heart failure in China.
Heart. 95:1727–1731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Chinese Society of Cardiology of Chinese
Medical Association; Editorial Board of Chinese Journal of
Cardiology: Chinese guidelines for the diagnosis and treatment of
heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi. 42:98–122.
2014.(In Chinese). PubMed/NCBI
|
|
3.
|
Mozaffarian D, Benjamin EJ, Go AS, Arnett
DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ,
Howard VJ, et al: American Heart Association Statistics Committee
and Stroke Statistics Subcommittee: Heart disease and stroke
statistics-2015 update: A report from the American Heart
Association. Circulation. 131:e29–322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Cicci JD, Reed BN, McNeely EB, Oni-Orisan
A, Patterson JH and Rodgers JE: Acute decompensated heart failure:
Evolving literature and implications for future practice.
Pharmacotherapy. 34:373–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Felker GM, Adams KF Jr, Konstam MA,
O'Connor CM and Gheorghiade M: The problem of decompensated heart
failure: Nomenclature, classification and risk stratification. Am
Heart J. 145(Suppl 2): S18–S25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Adams KF Jr, Fonarow GC, Emerman CL,
LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M and
Horton DP: ADHERE Scientific Advisory Committee and Investigators:
Characteristics and outcomes of patients hospitalized for heart
failure in the United States: rationale, design and preliminary
observations from the first 100,000 cases in the Acute
Decompensated Heart Failure National Registry (ADHERE). Am Heart J.
149:209–216. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zannad F, Mebazaa A, Juillière Y,
Cohen-Solal A, Guize L, Alla F, Rougé P, Blin P, Barlet MH,
Paolozzi L, et al: Clinical profile, contemporary management and
one-year mortality in patients with severe acute heart failure
syndromes: The EFICA study. Eur J Heart Fail. 8:697–705. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Piper S and McDonagh T: The role of
intravenous vasodilators in acute heart failure management. Eur J
Heart Fail. 16:827–834. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Levy PD, Laribi S and Mebazaa A:
Vasodilators in acute heart failure: Review of the latest studies.
Curr Emerg Hosp Med Rep. 2:126–132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Elkayam U, Janmohamed M, Habib M and
Hatamizadeh P: Vasodilators in the management of acute heart
failure. Crit Care Med. 36(Suppl 1): S95–S105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hollenberg SM: Vasodilators in acute heart
failure. Heart Fail Rev. 12:143–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Metra M, Teerlink JR, Voors AA, Felker GM,
Milo-Cotter O, Weatherley B, Dittrich H and Cotter G: Vasodilators
in the treatment of acute heart failure: What we know, what we
don't. Heart Fail Rev. 14:299–307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Elkayam U, Bitar F, Akhter MW, Khan S,
Patrus S and Derakhshani M: Intravenous nitroglycerin in the
treatment of decompensated heart failure: Potential benefits and
limitations. J Cardiovasc Pharmacol Ther. 9:227–241. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
den Uil CA and Brugts JJ: Impact of
intravenous nitroglycerin in the management of acute decompensated
heart failure. Curr Heart Fail Rep. 12:87–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Buch J: Urapidil, a dual-acting
antihypertensive agent: Current usage considerations. Adv Ther.
27:426–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Tebbe U, Wurst W and Neuhaus KL: Acute
haemodynamic effects of urapidil in patients with chronic left
ventricular failure. Eur J Clin Pharmacol. 35:305–308. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yang W, Zhou YJ, Fu Y, Qin J, Qin S, Chen
XM, Guo JC and Hua Q: A multicenter, randomized, trial comparing
urapidil and nitroglycerin in multifactor heart failure in the
elderly. Am J Med Sci. 350:109–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Liu LS: Writing Group of 2010 Chinese
Guidelines for the Management of Hypertension: 2010 Chinese
guidelines for the management of hypertension. Zhonghua Xin Xue
Guan Bing Za Zhi. 39:579–615. 2011.(In Chinese). PubMed/NCBI
|
|
19.
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL
and Johnson MR: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American College of Cardiology
Foundation/American Heart Association Task Force on practice
guidelines. J Am Coll Cardiol. 62:e147–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cherney D and Straus S: Management of
patients with hypertensive urgencies and emergencies: a systematic
review of the literature. J Gen Intern Med. 17:937–945. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zink M, Gombotz H, Wasler A, Grasser B,
Rehak P and Metzler H: Urapidil reduces elevated pulmonary vascular
resistance in patients before heart transplantation. J Heart Lung
Transplant. 21:347–353. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Drobinski G, Montalescot G, Fossier JM and
Grosgogeat Y: Effects of urapidil by intravenous injection on
pulmonary circulation and cardiac function in left ventricular
failure. Ann Cardiol Angeiol (Paris). 42:167–172. 1993.PubMed/NCBI
|
|
23.
|
Carlson MD and Eckman PM: Review of
vasodilators in acute decompensated heart failure: The old and the
new. J Card Fail. 19:478–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Fermann GJ and Collins SP: Initial
management of patients with acute heart failure. Heart Fail Clin.
9:291–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Carlyle PF and Cohn JN: Systemic and
regional hemodynamic effects of alpha-adrenoceptor blockade in
chronic left ventricular dysfunction in the conscious dog. Am Heart
J. 120:619–624. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wang RY, Chow JS, Chan KH, Pan HY and Wong
RP: Acute haemodynamic and myocardial metabolic effects of
intravenous urapidil in severe heart failure. Eur Heart J.
5:745–751. 1984.PubMed/NCBI
|
|
27.
|
M'Buyamba-Kabangu JR, Bielen E, Staessen
J, Fagard R, Lijnen P, Van Hoof R and Amery A: Hemodynamic effects
of urapidil in men. Presse Med. 19:1407–1411. 1990.PubMed/NCBI
|
|
28.
|
Toma M, Ezekowitz JA, Bakal JA, O'Connor
CM, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K and
Armstrong PW: The relationship between left ventricular ejection
fraction and mortality in patients with acute heart failure:
Insights from the ASCEND-HF Trial. Eur J Heart Fail. 16:334–341.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Bhardwaj A and Januzzi JL Jr: Natriuretic
peptide-guided management of acutely destabilized heart failure:
Rationale and treatment algorithm. Crit Pathw Cardiol. 8:146–150.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Parissis JT, Nikolaou M, Mebazaa A,
Ikonomidis I, Delgado J, Vilas-Boas F, Paraskevaidis I, McLean A,
Kremastinos D and Follath F: Acute pulmonary oedema: Clinical
characteristics, prognostic factors and in-hospital management. Eur
J Heart Fail. 12:1193–1202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kozàkovà M, Marco J, Heusch G, Bernies M,
Bossi IM, Palombo C, Anguissola GB, Donatelli F, Laurent JP and
Gregorini L: The alpha1-adrenergic blocker urapidil improves
contractile function in patients 3 months after coronary stenting:
A randomized, double-blinded study. Am Heart J. 147:E62004.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yao DK, Jia SQ, Wang L, Li HW, Zhang YC,
Wang YL and Wang LX: Therapeutic effect of urapidil on myocardial
perfusion in patients with ST-elevation acute coronary syndrome.
Eur J Intern Med. 20:152–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Oren S, Turkot S, Paran E, Flandra O,
Slezak L and Hof B: Efficacy and tolerability of slow release
urapidil (ebrantil) in hypertensive patients with non-insulin
dependent diabetes mellitus (NIDDM). J Hum Hypertens. 10:123–127.
1996.PubMed/NCBI
|
